Life Sciences

  • Microbiome / Nutrition / Foodtech / Lifestyle
  • Medtech / Connected health / Digital health
  • Biotech & pharmaceuticals
  • Industrial Biotech & Cleantech
  • Animal health / Animal Feed & Nutrition

Read more

Digital Technologies

  • Fintech
  • Retailtech
  • Other digital innovative solutions
  • Hardware & telecom

Read more

Sport & Performance Capital

  • Sport-Health
  • Equipment
  • Food-Nutrition
  • IOT-Digital
  • Sports practice

Read more

Blue Economy

  • Sustainable aquaculture
  • Nutrition Cosmetics Health
  • Industrial Products & Biomaterials
  • Biopolymers and biopackaging
  • Digitalization Blue 3.0
  • Recycling, Bioremediation
  • Climate & Carbon
  • Bioenergies, hydrogen

Read more

News

  • Zenniz Completes $6 Million Raise, Establishing USA HQ
    20 February 2026

    Zenniz Completes $6 Million Raise, Establishing USA HQ

    Zenniz, the world's leading provider of smart tennis...

  • Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
    11 February 2026

    Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis

    Microbiotica, a clinical-stage biopharma company...

  • Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors
    29 January 2026

    Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors

    Enterome SA, a clinical-stage company pioneering...

  • ErVimmune raises €17 million in Series A first closing to enter clinical development with lead cancer vaccine candidate
    21 January 2026

    ErVimmune raises €17 million in Series A first closing to enter clinical development with lead cancer vaccine candidate

    ErVimmune, a biotechnology company developing...

  • MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis
    20 January 2026

    MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis

    MaaT Pharma Announces First Patient Randomized in...